2020
Response to Epigenetic Disruption in Tumor Suppressor of Hepatocellular Carcinoma (HCC)
Luna A, Wu Q, Hlady R, Sathyanarayan A, Rustgi V, Guarrera J, Robertson K, Liu C. Response to Epigenetic Disruption in Tumor Suppressor of Hepatocellular Carcinoma (HCC). The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.08693.Peer-Reviewed Original ResearchHepatocellular carcinomaCancer risk detectionInhibitor 5-aza-2'-deoxycytidineHepatocellular carcinoma detectionHepatocellular carcinoma patientsEpigenetic changesHepatocellular carcinoma tumorsHuh7.5 cellsImproved treatment optionsHCC cell linesGene promoter sitesStressed cellsTreatment optionsTumor formationEpigenetic disruptionEffective treatmentGenetic mutationsLiver cancerEpigenetic dysregulationTumorMethylation inhibitorSuppressor of hepatocellular carcinomaTumor pathwaysWestern blot showEpigenetic events
2008
Identification of Liver Cancer-Specific Aptamers Using Whole Live Cells
Shangguan D, Meng L, Cao Z, Xiao Z, Fang X, Li Y, Cardona D, Witek R, Liu C, Tan W. Identification of Liver Cancer-Specific Aptamers Using Whole Live Cells. Analytical Chemistry 2008, 80: 721-728. PMID: 18177018, DOI: 10.1021/ac701962v.Peer-Reviewed Original ResearchConceptsLiver cancerLiver cancer cellsEarly diagnosisCell linesBALB/cJ miceCancer cellsSurgical resectionClinical outcomesLiver cell lineEffective treatmentMouse modelWhole live cellsDeadly cancerCurrent studyCancer-specific aptamersTumor selectionBasic mechanism studiesCancerMost cancersBNL CLCancer early diagnosisCell-SELEX methodNoncancer cell linesDiagnosisCancer recognition